IBEX LTD (IBEX) Fundamental Analysis & Valuation

NASDAQ:IBEX • BMG4690M1010

30.52 USD
+0.4 (+1.33%)
At close: Mar 6, 2026
30.52 USD
0 (0%)
After Hours: 3/6/2026, 8:25:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IBEX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

IBEX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 86 industry peers in the IT Services industry. IBEX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. An interesting combination arises when we look at growth and value: IBEX is growing strongly while it also seems undervalued. These ratings could make IBEX a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

7

1. IBEX Profitability Analysis

1.1 Basic Checks

  • IBEX had positive earnings in the past year.
  • IBEX had a positive operating cash flow in the past year.
  • IBEX had positive earnings in each of the past 5 years.
  • Each year in the past 5 years IBEX had a positive operating cash flow.
IBEX Yearly Net Income VS EBIT VS OCF VS FCFIBEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

1.2 Ratios

  • With an excellent Return On Assets value of 14.98%, IBEX belongs to the best of the industry, outperforming 94.19% of the companies in the same industry.
  • IBEX has a Return On Equity of 28.69%. This is amongst the best in the industry. IBEX outperforms 89.53% of its industry peers.
  • With an excellent Return On Invested Capital value of 21.96%, IBEX belongs to the best of the industry, outperforming 95.35% of the companies in the same industry.
Industry RankSector Rank
ROA 14.98%
ROE 28.69%
ROIC 21.96%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBEX Yearly ROA, ROE, ROICIBEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • Looking at the Profit Margin, with a value of 7.35%, IBEX is in the better half of the industry, outperforming 70.93% of the companies in the same industry.
  • In the last couple of years the Profit Margin of IBEX has grown nicely.
  • Looking at the Operating Margin, with a value of 9.38%, IBEX is in the better half of the industry, outperforming 66.28% of the companies in the same industry.
  • IBEX's Operating Margin has improved in the last couple of years.
  • IBEX's Gross Margin of 30.36% is in line compared to the rest of the industry. IBEX outperforms 43.02% of its industry peers.
  • IBEX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 9.38%
PM (TTM) 7.35%
GM 30.36%
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
IBEX Yearly Profit, Operating, Gross MarginsIBEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IBEX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IBEX is creating value.
  • There is no outstanding debt for IBEX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBEX Yearly Shares OutstandingIBEX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IBEX Yearly Total Debt VS Total AssetsIBEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 4.92 indicates that IBEX is not in any danger for bankruptcy at the moment.
  • IBEX's Altman-Z score of 4.92 is fine compared to the rest of the industry. IBEX outperforms 79.07% of its industry peers.
  • The Debt to FCF ratio of IBEX is 0.05, which is an excellent value as it means it would take IBEX, only 0.05 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.05, IBEX belongs to the top of the industry, outperforming 90.70% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that IBEX is not too dependend on debt financing.
  • The Debt to Equity ratio of IBEX (0.00) is better than 83.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Altman-Z 4.92
ROIC/WACC2.32
WACC9.47%
IBEX Yearly LT Debt VS Equity VS FCFIBEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.83 indicates that IBEX should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.83, IBEX perfoms like the industry average, outperforming 53.49% of the companies in the same industry.
  • A Quick Ratio of 1.83 indicates that IBEX should not have too much problems paying its short term obligations.
  • IBEX has a Quick ratio (1.83) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
IBEX Yearly Current Assets VS Current LiabilitesIBEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. IBEX Growth Analysis

3.1 Past

  • IBEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.77%, which is quite impressive.
  • Measured over the past years, IBEX shows a very strong growth in Earnings Per Share. The EPS has been growing by 41.04% on average per year.
  • IBEX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.63%.
  • IBEX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.62% yearly.
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
Revenue 1Y (TTM)15.63%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.72% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 9.67% on average over the next years. This is quite good.
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.82%
Revenue Next 2Y9.67%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBEX Yearly Revenue VS EstimatesIBEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
IBEX Yearly EPS VS EstimatesIBEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. IBEX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 8.82 indicates a reasonable valuation of IBEX.
  • Compared to the rest of the industry, the Price/Earnings ratio of IBEX indicates a rather cheap valuation: IBEX is cheaper than 90.70% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.29, IBEX is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 8.43, the valuation of IBEX can be described as reasonable.
  • 90.70% of the companies in the same industry are more expensive than IBEX, based on the Price/Forward Earnings ratio.
  • IBEX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.57.
Industry RankSector Rank
PE 8.82
Fwd PE 8.43
IBEX Price Earnings VS Forward Price EarningsIBEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • IBEX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IBEX is cheaper than 90.70% of the companies in the same industry.
  • 74.42% of the companies in the same industry are more expensive than IBEX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.98
EV/EBITDA 5.25
IBEX Per share dataIBEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • IBEX has a very decent profitability rating, which may justify a higher PE ratio.
  • IBEX's earnings are expected to grow with 13.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.38
PEG (5Y)0.21
EPS Next 2Y13.72%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IBEX Dividend Analysis

5.1 Amount

  • IBEX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBEX Fundamentals: All Metrics, Ratios and Statistics

IBEX LTD

NASDAQ:IBEX (3/6/2026, 8:25:11 PM)

After market: 30.52 0 (0%)

30.52

+0.4 (+1.33%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners96.38%
Inst Owner Change3.56%
Ins Owners6.19%
Ins Owner Change14.97%
Market Cap409.27M
Revenue(TTM)603.27M
Net Income(TTM)44.32M
Analysts45.71
Price Target41.82 (37.02%)
Short Float %1.24%
Short Ratio1.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.35%
Min EPS beat(2)8.65%
Max EPS beat(2)20.05%
EPS beat(4)4
Avg EPS beat(4)15.36%
Min EPS beat(4)8.65%
Max EPS beat(4)21.85%
EPS beat(8)8
Avg EPS beat(8)15.45%
EPS beat(12)10
Avg EPS beat(12)11.12%
EPS beat(16)13
Avg EPS beat(16)15.27%
Revenue beat(2)2
Avg Revenue beat(2)3.02%
Min Revenue beat(2)2.5%
Max Revenue beat(2)3.54%
Revenue beat(4)4
Avg Revenue beat(4)4.92%
Min Revenue beat(4)2.5%
Max Revenue beat(4)8.52%
Revenue beat(8)6
Avg Revenue beat(8)2.69%
Revenue beat(12)6
Avg Revenue beat(12)0.39%
Revenue beat(16)7
Avg Revenue beat(16)-0.19%
PT rev (1m)0%
PT rev (3m)6.49%
EPS NQ rev (1m)-2.2%
EPS NQ rev (3m)-2.2%
EPS NY rev (1m)0%
EPS NY rev (3m)5.47%
Revenue NQ rev (1m)0.91%
Revenue NQ rev (3m)0.91%
Revenue NY rev (1m)0.89%
Revenue NY rev (3m)2.72%
Valuation
Industry RankSector Rank
PE 8.82
Fwd PE 8.43
P/S 0.68
P/FCF 13.98
P/OCF 6.93
P/B 2.65
P/tB 2.87
EV/EBITDA 5.25
EPS(TTM)3.46
EY11.34%
EPS(NY)3.62
Fwd EY11.86%
FCF(TTM)2.18
FCFY7.15%
OCF(TTM)4.41
OCFY14.44%
SpS44.99
BVpS11.52
TBVpS10.64
PEG (NY)0.38
PEG (5Y)0.21
Graham Number29.95
Profitability
Industry RankSector Rank
ROA 14.98%
ROE 28.69%
ROCE 27.05%
ROIC 21.96%
ROICexc 23.71%
ROICexgc 25.25%
OM 9.38%
PM (TTM) 7.35%
GM 30.36%
FCFM 4.85%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Debt/EBITDA 0.01
Cap/Depr 168.3%
Cap/Sales 4.94%
Interest Coverage 42.98
Cash Conversion 79.5%
Profit Quality 66.06%
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z 4.92
F-Score8
WACC9.47%
ROIC/WACC2.32
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)15.63%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%
Revenue Next Year13.82%
Revenue Next 2Y9.67%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.68%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.53%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y85.57%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%

IBEX LTD / IBEX FAQ

Can you provide the ChartMill fundamental rating for IBEX LTD?

ChartMill assigns a fundamental rating of 7 / 10 to IBEX.


What is the valuation status for IBEX stock?

ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.


What is the profitability of IBEX stock?

IBEX LTD (IBEX) has a profitability rating of 7 / 10.


What is the valuation of IBEX LTD based on its PE and PB ratios?

The Price/Earnings (PE) ratio for IBEX LTD (IBEX) is 8.82 and the Price/Book (PB) ratio is 2.65.


Is the dividend of IBEX LTD sustainable?

The dividend rating of IBEX LTD (IBEX) is 0 / 10 and the dividend payout ratio is 0%.